BioSpace News Archive

Johnson & Johnson announced updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of investigational TAR-200 monotherapy in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer with carcinoma in situ, who are ineligible for, or decline, radical cystectomy.

CG Oncology, Inc. today announced that data from the Phase 3 BOND-003 study evaluating the efficacy and safety of cretostimogene monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG), showed that 75.2% of patients (79 out of 105 [95% confidence interval (CI), 65-83]) achieved a complete response (CR) at any time, as of the cutoff date of April 1, 2024.

BioSig Technologies, Inc. or, a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, announced new appointments to its now fully constituted board of directors, which is comprised of a total of five directors, three of whom are classified as independent directors.

Johnson & Johnson announced results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® and androgen deprivation therapy in patients with HRLPC who have undergone radical prostatectomy.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for children and adolescents with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency enrolled in the study, along with CAHtalog™ Registry data assessing glucocorticoid treatment patterns in pediatric and adult patients with CAH.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Mural Oncology plc announced that on May 1, the Company granted to three newly hired employees non-statutory stock options to purchase an aggregate of 20,150 ordinary shares of the Company and restricted stock units with respect to an aggregate of 10,850 ordinary shares of the Company, pursuant to the Company’s 2024 Inducement Stock Option and Incentive Plan.

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 160,500 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 117,000 shares of Arcutis’ common stock to 13 newly hired employees.

Terns Pharmaceuticals, Inc. announced that it has granted as of May 1, 2024 an equity inducement award to Melita Sun Jung, the Company’s new Chief Business Officer, under the terms of the 2022 Employment Inducement Award Plan, as amended.

NewAmsterdam Pharma Company N.V. announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 30,000 of NewAmsterdam’s ordinary shares to three non-executive new hires.